Dalbavancin During the COVID-19 Pandemic
- PMID: 36265122
- DOI: 10.52198/22.STI.41.WH1588
Dalbavancin During the COVID-19 Pandemic
Abstract
The COVID-19 pandemic, which started in March of 2020, and its associated surges have had an immense impact on the ability of medical staff to perform their daily activities. Thus, we sought to direct patients who had gram-positive Acute Bacterial Skin and Skin Structure Infections (ABSSSI) to our Outpatient Department/Wound Care Center for treatment. We met the challenge of the pandemic by shifting care in the treatment of ABSSSI using a new antibiotic delivery system. We examined the use and cost-effectiveness of Dalbavancin, a unique long-acting lipoglycopeptide antibiotic that is used in the treatment of acute bacterial skin and skin structure infections, during the COVID-19 pandemic. A total of 631 patients were treated in the Outpatient Department/Wound Care Center, with re-evaluation at the Wound Care Center on Day 3 post-infusion. The primary test of cure or major improvement was based on a 4- to 6-week re-assessment by the Wound Care Center Faculty (i.e., Podiatric, Vascular, Plastics, and Infectious Diseases). Treatment effectiveness was determined by examining documentation at follow-up. We also looked at the number of Outpatient Department treatments at the Wound Care Center for the periods 2018-2019 and 2020-2021. The shift of patients from the Emergency Department/Inpatient Department to the Outpatient Department/Wound Care Center was made possible by the use of the novel, streamlined, safe, Food and Drug Administration (FDA)-approved, well-tolerated antibiotic Dalbavancin. Dalbavancin is not prescribed for gram-negative infections, or for random prescribing, contamination, colonization, or prophylaxis. Dalbavancin has a low infusion reaction, low toxicity, long half-life, and low incidence of adverse reactions. Use of this medication was helpful for decreasing the inpatient burden in our facility.
Similar articles
-
Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.Microbiol Spectr. 2023 Feb 14;11(1):e0238522. doi: 10.1128/spectrum.02385-22. Epub 2022 Dec 20. Microbiol Spectr. 2023. PMID: 36537818 Free PMC article.
-
A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.Expert Opin Pharmacother. 2018 Mar;19(4):319-325. doi: 10.1080/14656566.2018.1442439. Epub 2018 Mar 6. Expert Opin Pharmacother. 2018. PMID: 29509504
-
Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).Ther Clin Risk Manag. 2016 Jun 7;12:931-40. doi: 10.2147/TCRM.S86330. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27354809 Free PMC article. Review.
-
Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.J Emerg Med. 2024 Mar 12:S0736-4679(24)00071-4. doi: 10.1016/j.jemermed.2024.03.003. Online ahead of print. J Emerg Med. 2024. PMID: 38825531
-
The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.Expert Rev Anti Infect Ther. 2021 Sep;19(9):1125-1134. doi: 10.1080/14787210.2021.1894130. Epub 2021 Mar 16. Expert Rev Anti Infect Ther. 2021. PMID: 33682593 Review.
Cited by
-
Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.Antibiotics (Basel). 2023 Jul 19;12(7):1205. doi: 10.3390/antibiotics12071205. Antibiotics (Basel). 2023. PMID: 37508301 Free PMC article.
LinkOut - more resources
Full Text Sources
Miscellaneous